|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ADRENALINE & SIMILAR DRUGS MAY ENHANCE THE CARDIAC SIDE EFFECTS OF LEVODOPA
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
AMPHETAMINES CAN ENHANCE THE ACTIVITY OF SYMPATHOMIMETIC AGENTS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|